Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COMPOUND 65 vs BIAXIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
COMPOUND 65 acts as a selective serotonin reuptake inhibitor (SSRI), increasing serotonin levels in the synaptic cleft by blocking the serotonin transporter (SERT).
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking peptide chain elongation.
Major depressive disorder (MDD),Generalized anxiety disorder (GAD),Obsessive-compulsive disorder (OCD)
Acute bacterial exacerbation of chronic bronchitis,Acute maxillary sinusitis,Community-acquired pneumonia,Pharyngitis/tonsillitis,Uncomplicated skin and skin structure infections,Helicobacter pylori eradication (as part of triple or dual therapy),Mycobacterium avium complex prophylaxis and treatment (off-label for some indications)
25 mg orally every 8 hours as needed for pain; maximum 75 mg per day.
250-500 mg orally every 12 hours for 7-14 days; extended-release: 1000 mg orally every 24 hours for 7-14 days
Terminal elimination half-life is 8-12 hours in healthy adults; prolonged to 15-20 hours in hepatic impairment; requires dose adjustment in severe hepatic disease.
Terminal elimination half-life: 3-7 hours (single dose, 250-500 mg); with multiple dosing, half-life may extend to 7-10 hours due to saturable metabolism. Clinical context: Shorter half-life requires twice-daily dosing; extended half-life (via 14-hydroxy metabolite, t1/2 ~11 h) contributes to antibacterial activity.
Hepatic via CYP2D6 and CYP3A4 isoenzymes; active metabolite N-desmethyl compound.
Primarily metabolized by CYP3A4 isoenzyme; clarithromycin undergoes first-pass metabolism to form 14-hydroxyclarithromycin (active metabolite).
Renal excretion of unchanged drug accounts for 30-40%; hepatic metabolism with fecal elimination of metabolites accounts for 50-60%; biliary excretion is minimal (<5%).
Approximately 20-30% of administered dose is excreted unchanged in urine; remainder is hepatically metabolized and excreted in bile and feces (~50% fecal elimination).
95-98% bound to serum albumin and alpha-1-acid glycoprotein.
65-75% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.8-1.2 L/kg, indicating extensive tissue distribution.
Vd: 2.6-3.5 L/kg. Clinical meaning: Large Vd indicates extensive tissue penetration, including lungs, tonsils, and sinuses, exceeding serum concentrations.
Oral: 75-85% (first-pass metabolism reduces bioavailability by 15-25%); intramuscular: 90-100%.
Oral bioavailability: 50-55% (250 mg tablet); may be increased to 60-70% when administered with food. Intravenous: 100%.
GFR 30-50 m L/min: 25 mg every 12 hours; GFR <30 m L/min: 25 mg every 24 hours; not recommended in dialysis.
Cr Cl <30 m L/min: reduce dose by 50%; Cr Cl <10 m L/min: not recommended; no adjustment for Cr Cl >30 m L/min
Child-Pugh A: no adjustment; Child-Pugh B: 12.5 mg every 12 hours; Child-Pugh C: not recommended.
Child-Pugh Class C: reduce dose by 50% or consider alternative; mild to moderate hepatic impairment: no adjustment
Children ≥12 years: 12.5-25 mg orally every 6-8 hours as needed; maximum 75 mg/day. Children <12 years: not established.
15 mg/kg/day orally divided every 12 hours; maximum 500 mg/day for 10 days; for extended-release, not recommended for children <12 years
Start at 12.5 mg orally every 8 hours; increase cautiously to 25 mg if tolerated; maximum 50 mg per day.
No specific dose adjustment; monitor renal function and adjust per renal guidelines; increased risk of QT prolongation
WARNING: Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults taking antidepressants. Monitor closely for worsening or emergence of suicidal thoughts and behaviors.
None
Serotonin syndrome,Increased risk of bleeding,Activation of mania/hypomania,Seizure risk,Angle-closure glaucoma risk,Sexual dysfunction
Increased risk of cardiac arrhythmias, including QT prolongation and torsades de pointes; avoid in patients with known QT prolongation or concurrent use with QT-prolonging drugs.,Potential for hepatotoxicity (elevated liver enzymes, hepatitis); monitor liver function.,Exacerbation of myasthenia gravis symptoms.,Clostridioides difficile-associated diarrhea (CDAD).,Drug interactions via CYP3A4 inhibition (e.g., statins, warfarin, colchicine, and other macrolides).,Pregnancy Category C; avoid use unless no alternative (clarithromycin associated with increased risk of miscarriage and fetal abnormalities in animal studies).
Concomitant use with MAOIs or within 14 days of MAOI therapy,Concomitant use with pimozide,Known hypersensitivity to COMPOUND 65 or any inactive ingredients
Hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic.,Concurrent use with pimozide, ergotamine, dihydroergotamine, lovastatin, simvastatin, or colchicine in renal/hepatic impairment.,History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.,QT prolongation or history of ventricular arrhythmias (including torsades de pointes).,Concurrent use with antiarrhythmics (e.g., quinidine, procainamide, amiodarone) or other QT-prolonging drugs.,Severe hepatic failure or acute porphyria.
Avoid alcohol consumption due to increased risk of hepatotoxicity and CNS depression. Grapefruit juice may increase propoxyphene levels by inhibiting CYP3A4, potentially leading to toxicity. High-fat meals may delay absorption but not significantly alter overall exposure. Maintain adequate hydration to prevent constipation.
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4 and may increase clarithromycin levels, raising risk of QT prolongation. High-fat meals may delay absorption but do not significantly alter total exposure. Alcohol is not specifically contraindicated but may increase gastrointestinal irritation; avoid concurrent use of statins (especially simvastatin, lovastatin) due to increased myopathy risk.
First trimester: Increased risk of congenital malformations, particularly neural tube defects and cardiac anomalies (based on animal studies and limited human data). Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal complications including withdrawal syndrome and respiratory depression at delivery.
FDA Pregnancy Category C. Animal studies have shown fetal harm (cleft palate, skeletal abnormalities) at doses 2-5 times the human clinical dose. No adequate human studies. First trimester: Avoid unless benefit justifies risk. Second and third trimesters: Limited data; use only if clearly needed. Monitor for potential maternal hepatotoxicity.
Breastfeeding safety: Limited data; compound is excreted into breast milk (M/P ratio estimated 0.80-1.20 based on molecular properties). Caution advised due to potential for infant sedation and withdrawal. Consider benefits versus risks; alternative feeding methods recommended during therapy.
Clarithromycin is excreted into human breast milk; the milk-to-plasma ratio is approximately 0.25-0.5. Infants exposed via breast milk may experience gastrointestinal disturbances or altered gut flora. Use with caution, especially in infants younger than 6 weeks of age due to risk of hypertrophic pyloric stenosis. Consider temporary discontinuation during therapy if high doses are used.
Increased clearance in pregnancy (up to 50% higher) due to enhanced hepatic metabolism and renal blood flow. Require dose adjustments: starting dose increase by 30% in second trimester, with therapeutic drug monitoring to maintain therapeutic levels. Postpartum return to pre-pregnancy dosing.
No specific pharmacokinetic studies have demonstrated a need for dose adjustment during pregnancy. However, pregnancy can increase volume of distribution and renal clearance; empirical dose monitoring is not required. Standard dosing regimens are applied unless hepatic or renal impairment is present.
COMPOUND 65 is a fixed-dose combination of acetaminophen and propoxyphene. Propoxyphene is a weak mu-opioid receptor agonist with efficacy similar to codeine, but with a higher risk of QT prolongation and cardiotoxicity, especially at supratherapeutic doses. Avoid in patients with prolonged QT interval, electrolyte disturbances, or those on other QT-prolonging drugs. Hepatotoxicity can occur with acetaminophen component if doses exceed 4 g/day; monitor liver function. Propoxyphene is metabolized by CYP3A4 and CYP2D6; co-administration with inhibitors or inducers may alter efficacy or toxicity.
Biaxin (clarithromycin) is a macrolide antibiotic with activity against atypical pathogens (e.g., Legionella, Mycoplasma, Chlamydia). It is a potent CYP3A4 inhibitor, increasing levels of statins, warfarin, and colchicine. Use caution in myasthenia gravis; may exacerbate weakness. QT prolongation risk: avoid use with other QT-prolonging drugs, correct electrolyte abnormalities. For H. pylori eradication, combine with amoxicillin and a PPI as first-line. Renal dose adjustment required for Cr Cl <30 m L/min.
Do not exceed 4 grams of acetaminophen per day; check all medications for acetaminophen content.,Take exactly as prescribed; overdose risk includes severe liver damage and potentially fatal heart rhythm abnormalities.,Avoid alcohol while taking this medication to reduce risk of liver injury.,Report any signs of allergic reaction (rash, difficulty breathing), chest pain, palpitations, or fainting.,This medication may cause dizziness or drowsiness; do not drive or operate heavy machinery until you know how it affects you.,Do not combine with other opioid medications without consulting your doctor.,Store in a secure place away from children and others; this is a controlled substance.,Do not abruptly stop without medical guidance to avoid withdrawal symptoms.
Take with or without food, but taking with food may reduce stomach upset.,Complete the full course even if you feel better to prevent resistance.,Avoid grapefruit or grapefruit juice while on this medication.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe nausea/vomiting.,May cause metallic or bitter taste in the mouth; this is usually temporary.,Tell your doctor if you have myasthenia gravis, as clarithromycin can worsen symptoms.,Avoid driving or operating heavy machinery if you experience dizziness or vision changes.,Use effective contraception if applicable; clarithromycin may reduce oral contraceptive efficacy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COMPOUND 65 vs BIAXIN, answered by our medical review team.
COMPOUND 65 is a Analgesic Combination (Opioid + NSAID) that works by COMPOUND 65 acts as a selective serotonin reuptake inhibitor (SSRI), increasing serotonin levels in the synaptic cleft by blocking the serotonin transporter (SERT).. BIAXIN is a Macrolide Antibiotic that works by Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking peptide chain elongation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COMPOUND 65 and BIAXIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COMPOUND 65 is: 25 mg orally every 8 hours as needed for pain; maximum 75 mg per day.. The standard adult dose of BIAXIN is: 250-500 mg orally every 12 hours for 7-14 days; extended-release: 1000 mg orally every 24 hours for 7-14 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COMPOUND 65 and BIAXIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COMPOUND 65 is classified as Category C. First trimester: Increased risk of congenital malformations, particularly neural tube defects and cardiac anomalies (based on animal studies and limited human data). Second trimest. BIAXIN is classified as Category C. FDA Pregnancy Category C. Animal studies have shown fetal harm (cleft palate, skeletal abnormalities) at doses 2-5 times the human clinical dose. No adequate human studies. First t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.